Vera Therapeutics, Inc. (VERA)
NASDAQ:VERA
Want to see VERA full AI Analyst Report?
VERA Stock Chart & Stats
$42.30
-$0.18(-0.43%)
At close: 4:00 PM EST
$42.30
-$0.18(-0.43%)
Day’s Range― - ―
52-Week Range$19.07 - $56.05
Previous CloseN/A
Volume142.65K
Average Volume (3M)1.01M
Market Cap
$2.24B
Enterprise Value$2.51B
Total Cash (Recent Filing)$596.76M
Total Debt (Recent Filing)$75.03M
Price to Earnings (P/E)―
Beta1.22
Next Earnings
Aug 06, 2026EPS Estimate
-1.6Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-5.54
Shares Outstanding71,782,906
10 Day Avg. Volume985,871
30 Day Avg. Volume1,006,189
Financial Highlights & Ratios
PEG Ratio-0.16
Price to Book (P/B)5.38
Price to Sales (P/S)0.00
P/FCF Ratio-13.46
Enterprise Value/Market Cap1.12
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit8.15K
Enterprise Value/Ebitda-6.92
Forecast
1Y Price Target
$79.00Price Target Upside86.76% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering11
EPS Forecast (FY)-6.07
Revenue Forecast (FY)$37.80M
Bulls Say, Bears Say
Bulls Say
Regulatory Progress: FDA AlignmentAgreement with the FDA to advance an earlier eGFR analysis materially shortens the regulatory timeline for atacicept. This structural alignment reduces regulatory uncertainty, raises the probability of a near-term sBLA filing, and could accelerate transition from clinical to commercial stage.
Low Leverage And Sizable EquityA low debt load and roughly $500M of equity provide financial flexibility to fund development programs without immediate high leverage. This stronger balance sheet footprint helps support ongoing trials and reduces short-term solvency risk versus peers relying heavily on debt.
Governance Continuity And Board SupportShareholder approval of board and governance measures, plus recent board additions, signal continuity and investor confidence in management strategy. Stable governance supports consistent clinical development execution and reduces leadership risk during critical regulatory milestones.
Bears Say
Pre-revenue Business ModelThe company remains pre-revenue with no product sales to offset R&D spending. Long-term value creation depends entirely on successful clinical outcomes and approval of atacicept or other candidates, making cash generation currently non-existent and future revenues binary and uncertain.
Large, Rising Operating Losses And Cash BurnRapidly widening net losses and increasing operating cash outflows indicate escalating funding needs. Persistent negative free cash flow drains equity and forces reliance on external capital, which can dilute shareholders and constrain investment timing for late-stage trials and commercialization prep.
Dependence On External Financing; Equity ErosionThe company funds R&D mainly via external financing while equity has eroded and returns on equity are deeply negative. This structural dependence increases dilution risk and makes the company vulnerable to market financing conditions when additional capital is required to reach potential approval and commercialization.
Vera Therapeutics News
VERA FAQ
What was Vera Therapeutics, Inc.’s price range in the past 12 months?
Vera Therapeutics, Inc. lowest stock price was $19.07 and its highest was $56.05 in the past 12 months.
What is Vera Therapeutics, Inc.’s market cap?
Vera Therapeutics, Inc.’s market cap is $2.24B.
When is Vera Therapeutics, Inc.’s upcoming earnings report date?
Vera Therapeutics, Inc.’s upcoming earnings report date is Aug 06, 2026 which is in 64 days.
How were Vera Therapeutics, Inc.’s earnings last quarter?
Vera Therapeutics, Inc. released its earnings results on May 07, 2026. The company reported -$1.69 earnings per share for the quarter, missing the consensus estimate of -$1.328 by -$0.362.
Is Vera Therapeutics, Inc. overvalued?
According to Wall Street analysts Vera Therapeutics, Inc.’s price is currently Undervalued.
Does Vera Therapeutics, Inc. pay dividends?
Vera Therapeutics, Inc. does not currently pay dividends.
What is Vera Therapeutics, Inc.’s EPS estimate?
Vera Therapeutics, Inc.’s EPS estimate is -1.6.
How many shares outstanding does Vera Therapeutics, Inc. have?
Vera Therapeutics, Inc. has 71,782,906 shares outstanding.
What happened to Vera Therapeutics, Inc.’s price movement after its last earnings report?
Vera Therapeutics, Inc. reported an EPS of -$1.69 in its last earnings report, missing expectations of -$1.328. Following the earnings report the stock price went down -1.954%.
Which hedge fund is a major shareholder of Vera Therapeutics, Inc.?
Currently, no hedge funds are holding shares in VERA
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Vera Therapeutics Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$79.00 (86.76% Upside)
$79.00 (86.76% Upside)
Blogger Sentiment
Bullish
VERA Sentiment 70%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 342.5K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days >0.1%
Last 30 Days ▼ 3.0%
Last 30 Days ▼ 3.0%
News Sentiment
Very Bullish
Bullish news 99%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-1.51%
12-Months-Change
Fundamentals
Return on Equity
-74.86%
Trailing 12-Months
Asset Growth
1.90%
Trailing 12-Months
Company Description
Vera Therapeutics, Inc.
Vera Therapeutics, Inc., a clinical stage biotechnology company, focuses on developing and commercializing treatments for patients with serious immunological diseases in the United States. Its lead product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection that is in Phase IIb clinical trial for patients with immunoglobulin A nephropathy. It is also developing MAU868, a monoclonal antibody for the treatment of BK viremia infections and is under Phase 2 clinical trial. The company was formerly known as Trucode Gene Repair, Inc. and changed its name to Vera Therapeutics, Inc. in April 2020. Vera Therapeutics, Inc. was incorporated in 2016 and is headquartered in Brisbane, California.
VERA Stock 12 Month Forecast
Average Price Target
$79.00
▲(86.76% Upside)
Technical Analysis
Viridian Therapeutics
―
Pharvaris
―
Edgewise Therapeutics
―
Janux Therapeutics Inc
―
Biohaven Ltd.
―
Ownership Overview
9.03% Insiders
16.38% Mutual Funds
50.20% Other Institutional Investors
9.42% Public Companies and
Individual Investors